Seagen Enters into License Agreement with Lava Therapeutics for LAVA-1223
By Ashish Tripathi
Pharma Deals Review: Vol 2022 Issue 10 (Table of Contents)
Published: 7 Oct-2022
DOI: 10.3833/pdr.v2022.i10.2730 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In a bid to expand its presence in solid tumours, Seagen has entered into a licensing agreement with Lava Therapeutics in a deal worth up to US$700 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS